Mukka Proteins IPO: Introduction
The Mukka Proteins IPO has been making waves in the financial world, drawing attention from investors, analysts, and industry enthusiasts. In this blog, we delve into the nitty-gritty of Mukka Proteins, its business model, financial performance, and the implications of its upcoming initial public offering.
Mukka Proteins IPO: Company Overview
Mukka Proteins is a prominent player in the fish protein industry in India. Notably, it stands out as one of the first Indian companies to commercialise Insect Protein—a game-changer in aqua feed, animal feed, and pet food.
Let’s explore the critical aspects of this company:
- Fish Protein Products:
Mukka Proteins manufactures fish protein products, including fish meal, oil, and soluble paste. These products are vital in the aqua, poultry, and pet food sectors. - Insect Protein:
The company’s innovative approach involves utilising insect meal and insect oil as ingredients. This move diversifies their product portfolio and positions them as pioneers in this emerging field. - Global Reach:
Mukka Proteins exports its products to over ten countries, including Bahrain, Bangladesh, China, Indonesia, Malaysia, Myanmar, the Philippines, Saudi Arabia, South Korea, Taiwan, and Vietnam.
Mukka Proteins IPO: Details
The Mukka Proteins IPO is an entirely fresh issue of shares with no offer for sale (OFS) component. Here are the critical details:
- Issue Size:
The company plans to issue 8 crores of fresh shares to the public. - Utilization of Funds:
The raised capital will be allocated towards working capital requirements, Investment in Ento Proteins’ working capital (a subsidiary), and general corporate purposes.
Mukka Proteins IPO: Issue Details:
- Issue Type:
Main Board IPO - Issue Size:
₹224 Crore - Issue Price:
₹26 – ₹28 per share - Open Date:
February 29, 2024 - Close Date:
March 4, 2024 - Listing Date:
March 7, 2024 (tentative) on BSE & NSE
Mukka Proteins IPO: Other Details:
- Offer Type:
Fresh Issue (no Offer for Sale) - Minimum Lot Size:
535 Shares - Minimum Investment:
₹14,980 - Book Running Lead Manager:
FedEx Securities Private Limited - Registrar:
Cameo Corporate Services Limited
Mukka Proteins IPO: Fundamental Analysis
Let’s dissect Mukka Proteins’ financial performance:
Revenue Growth:
Over the last three fiscal years, the company grew from ₹5,492.48 million in 2020 to ₹7,705.03 million in 2022. This upward trajectory bodes well for investors.
Profitability:
While the Profit and Loss After Tax exhibited volatility, the trend is positive. After a dip in 2021, profits rebounded significantly in 2022, reaching ₹258.19 million.
Return on Net Worth (RoNW):
The RoNW has improved, hitting 27.75% in 2022. Efficient utilisation of shareholders’ funds indicates a positive outlook.
Earnings per Share (EPS):
The diluted EPS rose from ₹0.60 in 2020 to ₹1.10 in 2022, signalling potential growth.
Debt-Equity Ratio:
The declining trend in the Debt-Equity ratio (from 242.46% in 2020 to 154.84% in 2022) reflects prudent financial management.
READ MORE: Exicom Tele Systems IPO: A Fundamental Analysis and Investment Opportunity
Conclusion
Investors looking to gain exposure to the exciting area of protein synthesis have a great chance with the Mukka Proteins IPO. Astute investors should watch this IPO closely as the company continues to innovate and expand its footprint. Please remember that careful investigation and due diligence are necessary before investing.
Notice: This site does not provide financial advice; it is merely informational. Seek advice from a qualified advisor before making any investments.
